Streptokinase morbidity — more common than previously recognised

W. J. Siebert, R. W. Ayres, M. T. Bulling, C. M. Thomas, R. B. Minson, P. E. Aylward

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Streptokinase is the thrombolytic agent most commonly used for the treatment of acute myocardial infarction. We report eight patients who developed late uncommon adverse reactions to streptokinase probably due to immune complex disease. The clinical manifestations included vasculitic rashes, abnormal renal and liver function tests and a syndrome resembling adult respiratory distress syndrome, Major adverse events with streptokinase such as stroke, bleeding and othet allergic reactions, have been previously documented but the morbidity related to delayed reactions has not been widely recognised. These reactions produced significant morbidity resulting in prolonged hospital stay and may need to be considered in the decision to use streptokinase. (Aust NZ J Med 1992; 22: 129–133.)

Original languageEnglish
Pages (from-to)129-133
Number of pages5
JournalAustralian and New Zealand Journal of Medicine
Volume22
Issue number2
DOIs
Publication statusPublished - Apr 1992

Keywords

  • adverse effects
  • myocardial infarction
  • Streptokinase

Fingerprint Dive into the research topics of 'Streptokinase morbidity — more common than previously recognised'. Together they form a unique fingerprint.

  • Cite this